We intend to focus our search on a target with operations or prospective operations in the technology, financial services, or media sectors, which we refer to as the “new economy sectors”, in Southeast Asia. Note: Peter Thiel, a co-founder of PayPal and the founder of Thiel Capital, is a backer of this newly organized blank […]

We intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector, with an emphasis on oncology and rare disease therapeutics where our management has extensive experience in investing, operating and drug development. Our founder and CEO is Luke Evnin of MPM Capital in Cambridge, Massachusetts. MPM Capital is […]

We intend to focus our search on telecommunications, media and technology (“TMT”) companies. Our management team, advisor and board of directors have had significant success sourcing, acquiring, expanding and monetizing these types of companies. We believe this experience makes us exceptionally well suited to identify, negotiate and successfully execute an initial business combination with the […]

(*Datto was priced at $27 – the top of its $24-to-$27 range – on 22 million shares on 10/20/20. Opened on 10/21/20 at $32, up 18.5 percent from its IPO price.) From the prospectus: Our mission is to create enterprise-grade technology for small and medium businesses delivered through our growing, global network of managed service […]

We intend to concentrate our efforts on identifying businesses in the financial services industry with a focus on delivering differentiated financial services in the wealth management, financial advisory and investment management sectors to the mass affluent and private client investor community.  Gary Wilder is our executive chairman. Michael Nessim is our CEO. Mr. Wilder is the group CEO […]

(Note: This is not an IPO, although the company says this is its IPO of American Depositary Shares (ADS) in the United States. From the prospectus: Each ADS represents represents eight ordinary shares. Our ordinary shares are listed on the Australian Securities Exchange under the symbol “OPT.” On Oct. 8, 2020, the last reported sale price […]

We are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives. Our lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of […]

We are a medical device company dedicated to improving the quality of life of people with hearing loss. We developed the Eargo solution to create a hearing aid that consumers actually want to use. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. […]

We intend to target early stage North American or European companies in the biotechnology sector of the healthcare industry where our management has extensive investment and operational experience. Our sponsor is an affiliate of 5AM Venture Management, LLC, or 5AM, a leading venture capital firm focused on building next-generation life science companies solving important healthcare […]

We are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the […]